Olema Pharmaceuticals’ (OLMA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Olema Pharmaceuticals (NASDAQ:OLMA) in a report published on Wednesday,Benzinga reports. They currently have a $30.00 price objective on the stock. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q4 2024 earnings at ($0.64) EPS, FY2024 earnings at ($2.34) EPS, FY2025 earnings at ($2.82) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($2.83) EPS and FY2028 earnings at ($2.43) EPS.

OLMA has been the subject of a number of other reports. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday, August 7th. JPMorgan Chase & Co. dropped their target price on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $27.00.

Olema Pharmaceuticals Stock Down 9.2 %

OLMA stock opened at $9.17 on Wednesday. The business’s 50-day moving average price is $12.00 and its 200-day moving average price is $11.97. Olema Pharmaceuticals has a twelve month low of $8.51 and a twelve month high of $17.10.

Hedge Funds Weigh In On Olema Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Conway Capital Management Inc. purchased a new position in shares of Olema Pharmaceuticals during the third quarter valued at about $119,000. Barclays PLC raised its holdings in shares of Olema Pharmaceuticals by 105.0% during the 3rd quarter. Barclays PLC now owns 94,915 shares of the company’s stock worth $1,133,000 after acquiring an additional 48,614 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of Olema Pharmaceuticals by 103.4% during the 3rd quarter. XTX Topco Ltd now owns 25,332 shares of the company’s stock worth $302,000 after acquiring an additional 12,878 shares in the last quarter. EP Wealth Advisors LLC boosted its position in shares of Olema Pharmaceuticals by 5.2% during the 3rd quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company’s stock valued at $581,000 after acquiring an additional 2,407 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Olema Pharmaceuticals by 10.8% in the third quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock valued at $11,972,000 after purchasing an additional 97,428 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.